A federal jury in California has ruled that Apple must pay medical device maker Masimo $634 million for violating a patent on blood oxygen monitoring technology. The jury found that features in the Apple Watch, such as workout mode and heart rate notifications, infringed on Masimo’s patent. Masimo, which is dedicated to developing technology that benefits patients, expressed satisfaction with the verdict and its commitment to defending its intellectual property rights.

Apple, however, plans to appeal the decision, arguing that the patent in question is specific to outdated patient monitoring technology. The legal dispute between the two companies centers on pulse oximetry, with Masimo accusing Apple of hiring away its employees and infringing on its patents in this area. The ongoing conflict has led to a ban on importing Apple Watches with blood oxygen monitoring features and the introduction of a new feature by Apple to circumvent this ban. Both companies continue to engage in legal battles surrounding the issue.